实用心脑肺血管病杂志
實用心腦肺血管病雜誌
실용심뇌폐혈관병잡지
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
2015年
7期
26-28,29
,共4页
心肌梗死%辛伐他汀%白细胞介素类%C反应蛋白质
心肌梗死%辛伐他汀%白細胞介素類%C反應蛋白質
심기경사%신벌타정%백세포개소류%C반응단백질
Myocardial infarction%Simvastatin%Interleukins%C-reactive protein
目的：观察辛伐他汀治疗急性心肌梗死的临床疗效及其对白介素17（ IL－17）、超敏C反应蛋白（ hs－CRP）的影响。方法选取2012年2月—2014年8月西安市西电集团医院收治的69例急性心肌梗死患者，根据入院时间顺序分成观察组35例和对照组34例。对照组患者给予常规治疗，观察组在对照组基础上采用辛伐他汀治疗，两组患者均治疗15 d。比较两组患者临床疗效、心血管不良事件发生情况，治疗前后血清IL－17水平、血浆hs－CRP水平及血脂指标〔总胆固醇（ TC）、三酰甘油（ TG）、低密度脂蛋白（ LDL）和高密度脂蛋白（ HDL）〕。结果观察组患者临床疗效优于对照组，差异有统计学意义（u＝3.090， P＝0.002）。治疗前两组患者血浆hs－CRP水平、血清IL－17水平比较，差异无统计学意义（P＞0.05）；治疗后观察组患者血浆hs－CRP水平、血清IL－17水平均低于对照组（P＜0.05）。治疗前两组患者TC、 TG、 LDL及HDL水平比较，差异无统计学意义（P＞0.05）；治疗后观察组患者TC、 TG、 LDL水平低于对照组， HDL水平高于对照组（ P＜0.05）。两组患者再次心肌梗死发生率和病死率比较，差异无统计学意义（P＞0.05）；观察组患者心律失常发生率低于对照组（P＜0.05）。结论辛伐他汀治疗急性心肌梗死患者的临床疗效确切，能有效降低血清IL－17、血浆hs－CRP水平，改善血脂，有助于减少心血管不良事件的发生。
目的：觀察辛伐他汀治療急性心肌梗死的臨床療效及其對白介素17（ IL－17）、超敏C反應蛋白（ hs－CRP）的影響。方法選取2012年2月—2014年8月西安市西電集糰醫院收治的69例急性心肌梗死患者，根據入院時間順序分成觀察組35例和對照組34例。對照組患者給予常規治療，觀察組在對照組基礎上採用辛伐他汀治療，兩組患者均治療15 d。比較兩組患者臨床療效、心血管不良事件髮生情況，治療前後血清IL－17水平、血漿hs－CRP水平及血脂指標〔總膽固醇（ TC）、三酰甘油（ TG）、低密度脂蛋白（ LDL）和高密度脂蛋白（ HDL）〕。結果觀察組患者臨床療效優于對照組，差異有統計學意義（u＝3.090， P＝0.002）。治療前兩組患者血漿hs－CRP水平、血清IL－17水平比較，差異無統計學意義（P＞0.05）；治療後觀察組患者血漿hs－CRP水平、血清IL－17水平均低于對照組（P＜0.05）。治療前兩組患者TC、 TG、 LDL及HDL水平比較，差異無統計學意義（P＞0.05）；治療後觀察組患者TC、 TG、 LDL水平低于對照組， HDL水平高于對照組（ P＜0.05）。兩組患者再次心肌梗死髮生率和病死率比較，差異無統計學意義（P＞0.05）；觀察組患者心律失常髮生率低于對照組（P＜0.05）。結論辛伐他汀治療急性心肌梗死患者的臨床療效確切，能有效降低血清IL－17、血漿hs－CRP水平，改善血脂，有助于減少心血管不良事件的髮生。
목적：관찰신벌타정치료급성심기경사적림상료효급기대백개소17（ IL－17）、초민C반응단백（ hs－CRP）적영향。방법선취2012년2월—2014년8월서안시서전집단의원수치적69례급성심기경사환자，근거입원시간순서분성관찰조35례화대조조34례。대조조환자급여상규치료，관찰조재대조조기출상채용신벌타정치료，량조환자균치료15 d。비교량조환자림상료효、심혈관불량사건발생정황，치료전후혈청IL－17수평、혈장hs－CRP수평급혈지지표〔총담고순（ TC）、삼선감유（ TG）、저밀도지단백（ LDL）화고밀도지단백（ HDL）〕。결과관찰조환자림상료효우우대조조，차이유통계학의의（u＝3.090， P＝0.002）。치료전량조환자혈장hs－CRP수평、혈청IL－17수평비교，차이무통계학의의（P＞0.05）；치료후관찰조환자혈장hs－CRP수평、혈청IL－17수평균저우대조조（P＜0.05）。치료전량조환자TC、 TG、 LDL급HDL수평비교，차이무통계학의의（P＞0.05）；치료후관찰조환자TC、 TG、 LDL수평저우대조조， HDL수평고우대조조（ P＜0.05）。량조환자재차심기경사발생솔화병사솔비교，차이무통계학의의（P＞0.05）；관찰조환자심률실상발생솔저우대조조（P＜0.05）。결론신벌타정치료급성심기경사환자적림상료효학절，능유효강저혈청IL－17、혈장hs－CRP수평，개선혈지，유조우감소심혈관불량사건적발생。
Objective To observe the clinical effect of simvastatin on acute myocardial infarction and its impact on IL-17 and hs-CRP.Methods A total of 69 patients with acute myocardial infarction were selected in the Hospital of China XD Group from February 2012 to August 2014, and they were divided into control group ( n=34) and observation group ( n=35) according to admission time.Patients of control group were given conventional treatment, while patients of observation group were given extra simvastatin based on conventional treatment, both groups treated for 15 days.Clinical effect, incidence of adverse cardiovascular events, serum IL -17 level, plasma hs -CRP level and blood lipid parameters ( including TC, TG, LDL, HDL) before and after treatment were compared between the two groups.Results The clinical effect of observation group was statistically significantly better than that of control group (u =3.090, P =0.002).No statistically significant differences of serum IL-17 level, plasma hs-CRP level, TC, TG, LDL or HDL was found between the two groups before treatment ( P>0.05); after treatment, serum IL-17 level, plasma hs-CRP level, TC, TG and LDL of observation group were statistically significantly lower than those of control group, while HDL of observation group was statistically significantly higher than that of control group (P<0.05).No statistically significant differences of incidence of re-infarction or fatality rate was found between the two groups, while incidence of arrhythmia of observation group was statistically significantly lower than that of control group (P<0.05).Conclusion Simvastatin is certainly effective in treating acute myocardial infarction, which can effectively reduce the serum IL-17 level and plasma hs -CRP level, improve the blood lipid, is helpful to reduce the incidence of adverse cardiovascular events.
